MedTrace Logo

Adrecizumab in Cardiogenic Shock

NCT03989531 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-10-08

No results posted yet for this study

Summary

Cardiogenic shock is a serious medical condition with high mortality and morbidity. This trial assesses safety, tolerability and efficacy of Adrecizumab on top of standard of care in patients with cardiogenic shock.

Conditions

  • Cardiogenic Shock
  • Endothelial Dysfunction

Interventions

BIOLOGICAL

Adrecizumab

Drip infusion over 60 minutes

DRUG

Placebo

Drip infusion over 60 minutes

Sponsors & Collaborators

  • Dr. med. Mahir Karakas

    lead OTHER

Principal Investigators

  • Mahir Karakas, MD, MBA · University Heart Center Hamburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-04
Primary Completion
2021-04-26
Completion
2021-04-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989531 on ClinicalTrials.gov